In the direct comparison of tirzepatide versus semaglutide, we observed CIs compatible with no difference and point estimates indicating a modest numeric advantage of semaglutide, if any, for reducing MACE, particularly among patients at high cardiovascular risk
contraindicated in patients with personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2), pancreatitis (discontinue if suspected), gallbladder disease, and acute kidney injury secondary to dehydration from gastrointestinal side effects
This means the body cant handle the excess fluid, leading to symptoms like swelling, high blood pressure, or shortness of breath (from fluid in lungs)
At 10 mg, average weight loss jumped to 21.4%, roughly 47 pounds from the same starting weight
Other protein sources have also been shown to stimulate GLP-1 release in vivo